Welcome to the Pentracor GmbH

Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.

C-reactive protein (CRP) is an antibody of prehistoric immune systems and the innate immune system. It binds to proteins of the complement system forming immunocomplexes. In heart attack and stroke CRP increases primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.

The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.

More about the treatmentAsk questions

PentraSorb® CRP

Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).

CRP Adsorber

In the case of organ damage (e.g. heart attack or stroke), CRP marks cells capable of regeneration, which are then eliminated by the immune system. This increases the primary damage.

With the help of the PentraSorb® CRP can be removed from the blood with the aim of reducing this damage.

Read More

CRP apheresis

In CRP apheresis, CRP is selectively removed from the patient's blood plasma.

The application of PentraSorb® CRP is comparable to dialysis and can be performed in an outpatient or inpatient setting.

During the treatment, blood plasma is passed through the PentraSorb® CRP, which then selectively removes CRP from it.

Read More


In principle, CRP reduction can induce therapeutic benefits in a number of acute and chronic diseases.

PentraSorb® CRP is a potential therapeutic option for diseases where elevated CRP levels are associated with a poor prognosis.

Read More


21.-22 October: ÖSKIM 2022

We are represented at the second Austrian Symposium for Cardiovascular Intensive Care Medicine (ÖSKIM 2022) with a stand and as a sponsor.


MPs visit Pentracor


Two MPs of the social democrats visited us last thursday.

MAZ reports "Pentracor could save lives, but is fighting for survival"


Although political attention has now been drawn to the topic and the state parliamentarians Andreas Noack and Björn Lüttmann have also visited the company, the situation is serious.

Who can and should pay for this? Pentacor in the Abendschau


The rbb broadcast a contribution in the Berliner Abendschau on CRP apheresis and the lack of funds, because “the examinations are complex, possible treatments are expensive. Who can and should pay for that?”

FDA grants designation as Breakthrough Device


The FDA has granted PentraSorb CRP designation as a Breakthrough Device. A remarkable achievement.

CRP-Apheresis at a loss!


The local newspaper MOZ reports financial problems of Pentracor, since health insurances have terminated payment for this treatment.

Feature Paper in Journal of Clinical Medicine


A further analyses of out CAMI-1 study hast been published as a feature paper in the Journal of Clinical Medicine.